07 December 2023>: Clinical Research
Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study
Beata Kotowicz 1ACDEF* , Anna Dańska-Bidzińska 2ABDEG , Małgorzata Fuksiewicz 1BCDE , Anna Nasierowska-Guttmejer 3BC , Dorota Raczkiewicz 4C , Mariusz Gujski 5BEF , Szymon Piątek 6B , Mariusz Bidziński 6AEGDOI: 10.12659/MSM.941562
Med Sci Monit 2023; 29:e941562
Table 4 The histopathological type of tumor, number of patients who died/number of all patients, the percentage of deaths, and the survival time in months.
Histopathological type | Death/all patients (%) | Survival (months) min–max; median |
---|---|---|
Carcinosarcoma | 16/18 (89) | 7–165; 16 |
Leiomyosarcoma | 9/13 (69) | 6–141; 36 |
High grade ESS | 6/10 (60) | 13–138; 21 |
Low grade ESS | 0/4 (0) | 101–149; 138 |
Adenosarcoma | 1/5 (20) | 69–157; 119 |
Rhabdomyosarcoma | 0/1 (0) | 142 |
Solitary fibrous tumour | 0/1 (0) | 138 |